Cargando…
Profiling of Amino Acids and Their Derivatives Biogenic Amines Before and After Antipsychotic Treatment in First-Episode Psychosis
Schizophrenia (SCH) is a heterogeneous disorder, deriving from a potential multitude of etiopathogenetic factors. During the past few years there has been an increasing interest in the role of circulating amino acids (AAs) and biogenic amines (BAs) in the pathophysiology of SCH. In the present study...
Autores principales: | Leppik, Liisa, Kriisa, Kärt, Koido, Kati, Koch, Kadri, Kajalaid, Kärolin, Haring, Liina, Vasar, Eero, Zilmer, Mihkel |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5928450/ https://www.ncbi.nlm.nih.gov/pubmed/29740359 http://dx.doi.org/10.3389/fpsyt.2018.00155 |
Ejemplares similares
-
Antipsychotic Treatment Reduces Indices of Oxidative Stress in First-Episode Psychosis Patients
por: Kriisa, Kärt, et al.
Publicado: (2016) -
Metabolomics approach revealed robust changes in amino acid and biogenic amine signatures in patients with schizophrenia in the early course of the disease
por: Parksepp, Madis, et al.
Publicado: (2020) -
Taurine and Epidermal Growth Factor Belong to the Signature of First-Episode Psychosis
por: Koido, Kati, et al.
Publicado: (2016) -
The Expanded Endocannabinoid System Contributes to Metabolic and Body Mass Shifts in First-Episode Schizophrenia: A 5-Year Follow-Up Study
por: Parksepp, Madis, et al.
Publicado: (2022) -
A Marked Low-Grade Inflammation and a Significant Deterioration in Metabolic Status in First-Episode Schizophrenia: A Five-Year Follow-Up Study
por: Parksepp, Madis, et al.
Publicado: (2022)